Arylamine N-acetyltransferase 1 (NAT1) genotypes in a Lebanese population

被引:22
作者
Dhaini, HR
Levy, GN
机构
[1] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Environm & Ind Hlth, Toxicol Program, Ann Arbor, MI 48109 USA
来源
PHARMACOGENETICS | 2000年 / 10卷 / 01期
关键词
N-acetyltransferase; NAT1; polymorphism; Lebanese; genotyping;
D O I
10.1097/00008571-200002000-00010
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The frequency distributions of human N-acetyltransferase 1 (NAT1*) alleles in various ethnic groups are largely unknown, This lack of information is in contrast to the many studies of ethnic differences in NAT2* alleles and phenotypes. Increasing interest in NAT1 due to its potential roles in carcinogen metabolism and cancer risk makes it desirable to know the distribution of NAT1* alleles in various populations. Using a polymerase chain reaction-restriction fragment length polymorphism genotyping assay, the frequency of NAT1* alleles in a Lebanese population was determined. Of 84 NAT1* alleles assayed, 56% were NAT1*4, Alleles NAT1*3, *10, and *14 were found at frequencies of 0.036, 0.107, and 0.238, respectively. Five additional alleles (6%) differed from previously reported alleles, Nearly 50% of the population were heterozygous for a NAT1*14 allele, The unusually high frequency of NAT1*14 alleles in Lebanese may be useful for epidemiological studies of the effects of the NAT1 polymorphism in this population. Pharmacogenetics 10:79-83 (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:79 / 83
页数:5
相关论文
共 23 条
[1]   GENOTYPE-PHENOTYPE DISCORDANCE FOR HUMAN ARYLAMINE N-ACETYLTRANSFERASE (NAT2) REVEALS A NEW SLOW-ACETYLATOR ALLELE COMMON IN AFRICAN-AMERICANS [J].
BELL, DA ;
TAYLOR, JA ;
BUTLER, MA ;
STEPHENS, EA ;
WIEST, J ;
BRUBAKER, LH ;
KADLUBAR, FF ;
LUCIER, GW .
CARCINOGENESIS, 1993, 14 (08) :1689-1692
[2]   N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk [J].
Bouchardy, C ;
Mitrunen, K ;
Wikman, H ;
Husgafvel-Pursiainen, K ;
Dayer, P ;
Benhamou, S ;
Hirvonen, A .
PHARMACOGENETICS, 1998, 8 (04) :291-298
[3]   Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G560A mutations [J].
Butcher, NJ ;
Ilett, KF ;
Minchin, RF .
PHARMACOGENETICS, 1998, 8 (01) :67-72
[4]   N-ACETYLTRANSFERASE PHENOTYPES IN IRAQI AND BRITISH-POPULATION [J].
CARTWRIGHT, RA ;
AHMAD, RA ;
ROGERS, HJ .
HUMAN HEREDITY, 1984, 34 (02) :101-104
[5]  
CASCORBI I, 1995, AM J HUM GENET, V57, P581
[6]   A restriction fragment length polymorphism assay that differentiates human N-acetyltransferase-1 (NAT1) alleles [J].
Deitz, AC ;
Doll, MA ;
Hein, DW .
ANALYTICAL BIOCHEMISTRY, 1997, 253 (02) :219-224
[7]   THE ACETYLATOR PHENOTYPES OF SAUDI-ARABIAN DIABETICS [J].
EVANS, DAP ;
PATERSON, S ;
FRANCISCO, P ;
ALVAREZ, G .
JOURNAL OF MEDICAL GENETICS, 1985, 22 (06) :479-483
[8]   UTILITY OF A SWISH AND SPIT TECHNIQUE FOR THE COLLECTION OF BUCCAL CELLS FOR TAP HAPLOTYPE DETERMINATION [J].
HAYNEY, MS ;
DIMANLIG, P ;
LIPSKY, JJ ;
POLAND, GA .
MAYO CLINIC PROCEEDINGS, 1995, 70 (10) :951-954
[9]   ACETYLATOR GENOTYPE AND ARYLAMINE-INDUCED CARCINOGENESIS [J].
HEIN, DW .
BIOCHIMICA ET BIOPHYSICA ACTA, 1988, 948 (01) :37-66
[10]   Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe [J].
Hughes, NC ;
Janezic, SA ;
McQueen, KL ;
Jewett, MAS ;
Castranio, T ;
Bell, DA ;
Grant, DM .
PHARMACOGENETICS, 1998, 8 (01) :55-66